As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Daratumumab for the treatment of relapsing or refractory multiple myeloma. This review discusses the indications and funding, dosage and administration, infusion management, contraindications and some key studies focussed on the use of Daratumumab.
Commentary is provided by Professor Miles Prince, Professor of Medicine at both Melbourne and Monash Universities and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare.
Please login below to download this issue (PDF)